Amplia Therapeutics
Updated: December 06, 2025
Christopher Burns, CEO
Country: Australia | Add Funding
Founded: 2016
Website: https://www.ampliatx.com/site/content/
Amplia Therapeutics develops focal adhesion kinase (FAK) inhibitors for the treatment of pancreatic and ovarian cancer. Focal adhesion kinase (FAK) is expressed in many types of cancer, where it maintains cell viability and stimulates cell growth and migration. Amplia's lead drug candidate, narmafotinib, is a highly selective and potent FAK inhibitor that has shown promising results in pancreatic cancer research. FAK inhibitors act on both the cancer cells themselves and surrounding tissue, making current and future treatments more vulnerable and responsive. Amplia has orphan drug designation, fast-track designation and an open application for pancreatic cancer treatment from the US FDA.
Founded: 2016
Website: https://www.ampliatx.com/site/content/
Amplia Therapeutics develops focal adhesion kinase (FAK) inhibitors for the treatment of pancreatic and ovarian cancer. Focal adhesion kinase (FAK) is expressed in many types of cancer, where it maintains cell viability and stimulates cell growth and migration. Amplia's lead drug candidate, narmafotinib, is a highly selective and potent FAK inhibitor that has shown promising results in pancreatic cancer research. FAK inhibitors act on both the cancer cells themselves and surrounding tissue, making current and future treatments more vulnerable and responsive. Amplia has orphan drug designation, fast-track designation and an open application for pancreatic cancer treatment from the US FDA.
